A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated non-squamous non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.9052
Abstract: 9052Background: Napabucasin is a first-in-class cancer stemness inhibitor, identified by its ability to inhibit STAT3-driven gene transcription and spherogenesis of cancer stem cells (Li et al PNAS... read more here.
Keywords: study napabucasin; weekly paclitaxel; paclitaxel advanced; cancer ... See more keywords
Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Nanomedicine"
DOI: 10.2147/ijn.s372477
Abstract: Background NK105 is a paclitaxel (PTX)-incorporating “core-shell-type” polymeric micellar nanoparticle formulation composed of block copolymers (polyethylene glycol and a polyamino acid). The efficacy and safety of NK105 and paclitaxel in advanced or recurrent breast cancer… read more here.
Keywords: recurrent breast; nk105 group; nk105 paclitaxel; group ... See more keywords